These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 19284377)

  • 1. Promising novel immunotherapies and combinations for prostate cancer.
    Arlen PM; Mohebtash M; Madan RA; Gulley JL
    Future Oncol; 2009 Mar; 5(2):187-96. PubMed ID: 19284377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current perspectives in prostate cancer vaccines.
    Arlen PM; Gulley JL
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1052-7. PubMed ID: 19719454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer vaccines: current directions and perspectives in prostate cancer.
    Mohebtash M; Gulley JL; Madan RA; Ferrara T; Arlen PM
    Curr Opin Mol Ther; 2009 Feb; 11(1):31-6. PubMed ID: 19169957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining immunotherapies for the treatment of prostate cancer.
    Redman JM; Gulley JL; Madan RA
    Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer immunotherapy.
    McNeel DG
    Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review.
    Janiczek M; Szylberg Ł; Kasperska A; Kowalewski A; Parol M; Antosik P; Radecka B; Marszałek A
    J Immunol Res; 2017; 2017():4861570. PubMed ID: 29109964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA vaccines for the treatment of prostate cancer.
    Alam S; McNeel DG
    Expert Rev Vaccines; 2010 Jul; 9(7):731-45. PubMed ID: 20624047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy: sipuleucel-T and beyond.
    Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
    Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in prostate cancer: emerging strategies against a formidable foe.
    Bilusic M; Heery C; Madan RA
    Vaccine; 2011 Sep; 29(38):6485-97. PubMed ID: 21741424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer vaccines in clinical trials.
    Lubaroff DM
    Expert Rev Vaccines; 2012 Jul; 11(7):857-68. PubMed ID: 22913261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
    Patel A; Fong L
    Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and clinical development of DNA vaccines for prostate cancer.
    Colluru VT; Johnson LE; Olson BM; McNeel DG
    Urol Oncol; 2016 Apr; 34(4):193-204. PubMed ID: 24332642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic prostate cancer vaccines: a review of the latest developments.
    Mohebtash M; Madan RA; Gulley JL; Arlen PM
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1296-301. PubMed ID: 19037836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating Immunotherapies in Prostate Cancer.
    Strauss J; Madan RA
    Curr Oncol Rep; 2015 Oct; 17(10):45. PubMed ID: 26275784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer vaccines: the long road to clinical application.
    Baxevanis CN; Papamichail M; Perez SA
    Cancer Immunol Immunother; 2015 Apr; 64(4):401-8. PubMed ID: 25690791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.
    Aragon-Ching JB; Williams KM; Gulley JL
    Front Biosci; 2007 Sep; 12():4957-71. PubMed ID: 17569623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic vaccines for prostate cancer.
    Cha E; Fong L
    Curr Opin Mol Ther; 2010 Feb; 12(1):77-85. PubMed ID: 20140819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.